Trial Profile
Phase Ib/II Study of ALT-803 in Combination With Gemcitabine and Nab-paclitaxel in Patients With Advanced Pancreatic Cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Inbakicept (Primary) ; Gemcitabine; Paclitaxel
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Altor BioScience Corporation
- 23 Aug 2019 Status changed from active, no longer recruiting to completed.
- 31 Oct 2017 Planned End Date changed from 1 Jul 2022 to 1 Jul 2020.
- 31 Oct 2017 Planned primary completion date changed from 1 Jul 2019 to 1 Jul 2018.